Thursday, November 14, 2013

- **POSTER (#LB-2117):** SCYX-7158 (AN5568): CNS Exposure Predicted from First-in-Human Clinical Studies Indicates a Single Oral Dose Treatment is Possible for Sterile Cures of Stage 2 Human African Trypanosomiasis  
  **Authors:** Stephen Wring, Eric Gaukel, Robert Jacobs, Sanjay Chanda, Virginie Gualano, Eric Evène, Yves Donazzolo, Mathilde Latreille, Robert Don, Charles Mowbray, Antoine Tarral  
  **Affiliations:**  
  1. Scynexis Inc, Research Triangle Park, NC, USA  
  2. Anacor Pharmaceuticals Inc, Palo Alto, CA, USA  
  3. PhinC Development, Evry, France  
  4. Eurofins Optimed, Gières, France  
  5. DNDi, Geneva, Switzerland
  
  **Session title:** 27. Poster Session A Presentations and Light Lunch
  **Session time:** 12:00-1:45 PM
  **Location:** Exhibit Hall B/C
  **Link:** [http://ow.ly/qiyzC](http://ow.ly/qiyzC)

- **SYMPOSIUM (Session #41):** Advances in Drug Discovery for Chagas Disease  
  **Session time:** 1:45-3:30 PM
  **Location:** Lincoln 2
  **Details:**  
  1. **Organizer:** Rick L. Tarleton, University of Georgia, Athens, GA, USA
  2. **1:45 PM:** *New tools and new leads for drugs for Chagas disease*, Rick L. Tarleton, University of Georgia, Athens, GA, USA
  3. **2:05 PM:** *CYP51 structure-based VNI scaffold development for Chagas disease*, Galina Lepesheva, Vanderbilt University, Nashville, TN, USA
  4. **2:25 PM:** *HTS discovery of new leads for treatment of T. cruzi infection*, Richard Glynne, Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA
o 2:45 PM: *HTS for T. cruzi infection of mammalian cells through GSK-Open Lab*, Ana Rodriguez, New York University, New York, NY, USA

**Link:** [http://ow.ly/qiBVm](http://ow.ly/qiBVm)

**Description:** The work of new public-private partnerships, input from big pharma and advances in drug discovery tools in academics has brought renewed life to drug discovery efforts in Chagas disease. This symposium will feature representatives from all of these groups in discussions of the state-of-the-art in drug discovery for treatment of Trypanosoma cruzi infection and the potential for development of new drugs in the future.

- **SYMPOSIUM (Session #53):** *Chagas Disease: Recent Advances in Research and Development*
  
  **Session time:** 4:00-5:45 PM  
  **Location:** Lincoln 2  
  **Details:**
  - Organizer: Isabela Ribeiro, Drugs for Neglected Diseases initiative, Geneva, Switzerland  
  - Co-Chair: Sergio Sosa-Estani, Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben", Buenos Aires, Argentina  
  - 4:00 PM: *E 1224—results of proof-of-concept clinical trial in patients with chronic indeterminate Chagas disease*, Faustino Torrico, Facultad de Medicina de la Universidad Mayor de San Simon, Cochabamba, Bolivia  
  - 4:20 PM: *Population-pharmacokinetics of benznidazole in children and adults with Chagas disease*, Jaime Altcheh, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina  
  - 4:40 PM: *TRAENA – placebo-controlled evaluation of impact of benznidazole treatment on long term disease progression in adults with chronic Chagas disease*, Adelina Riarte, Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben", Buenos Aires, Argentina  
  - 5:00 PM: *Advances in biological markers of therapeutic response in Chagas disease*, Maria Jesus Pinazo, CRESIB - Barcelona Centre for International Health Research, Barcelona, Spain; Alejandro Schijman, CONICET - INGEBI, Argentina, Buenos Aires, Argentina

**Link:** [http://ow.ly/qiCA1](http://ow.ly/qiCA1)

**Description:** Chagas disease ranks among the world’s most neglected diseases. After decades of limited progress, the last few years have witnessed a significant change in the landscape of research and drug development in Chagas disease. The proposed symposium will provide an overview of new data on old compounds, treatment regimens, new drug candidates and biological markers from key experts in the field. The first presentation will provide the announcement of the results of the first clinical trial of E1224, a pro-drug of ravuconazole, in the treatment of Chagas disease in adults with chronic indeterminate Chagas disease. The second presentation will summarize new data on pharmacokinetics and pharmacodynamics of benznidazole in the treatment of adults and children with Chagas disease. The third presentation will describe the results of the TRAENA clinical trial, a placebo-controlled evaluation of the efficacy and safety of benznidazole in adult patients with chronic Chagas disease. This study involves follow-up of patients for approximately 10 years with assessment of long-term disease progression. The fourth and last presentation will provide a review of recent advances in biological markers of therapeutic response.
• **SIDE EVENT:** *Advancing Life-Saving R&D Innovations for People Living with Chagas Diseases – The Silent Killer* (Discussion and Reception)

**Event time:** 6:30-7:30 PM

**Location (OFF SITE):** PAHO Headquarters, 525 23rd St NW, Room B, Washington, DC

**Organizers/sponsors:** DNDi, Sabin Vaccine Institute/National School of Tropical Medicine at Baylor College of Medicine, Doctors Without Borders/Médecins Sans Frontières (MSF), Global Chagas Disease Coalition, Research!America, ASTMH, and PAHO

**Program/speakers:**
- Introduction and video
- Dr. Peter Hotez, Sabin/NSTM/BCM
- **Dr. Isabela Ribeiro, DNDi**
- Jenny Sanchez and Dr. Rachel Marcus, LaSocha, US Chagas disease patients association
- Sonia Tarragona, Mundo Sano; representing the Global Chagas Disease Coalition
- Dr. Luis Gerardo Castellanos, PAHO
- Panel discussion, moderated by Dr. Estrella Lasry, MSF

**Link:** [http://ow.ly/qiJej](http://ow.ly/qiJej)

**Description:** Please join us for an evening panel discussion and reception on developing new and innovative life-saving health tools for patients afflicted with Chagas disease, the leading parasitic killer of the Americas. Coinciding with the American Society of Tropical Medicine and Hygiene (ASTMH) 62nd Annual Meeting, this complementary side event will bring together patients, researchers, clinicians, and policymakers to shed light on the treatment and research needs of people living with Chagas disease. Chagas disease is a silent killer in Latin America, the US, and internationally. Much more needs to be done today to save the lives of neglected Chagas disease patients, including scaling up screening and treatment, and boosting R&D of new health tools, including drugs, vaccines, and diagnostics.

---

**Friday, November 15, 2013**

• **POSTER (#813):** *Efficacy, Safety, and Population-Pharmacokinetics of the Artesunate-Mefloquine (ASMQ) fixed dose combination versus Artemether-Lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in African children*

**Authors:** Monia Guidi,1,2 Laurent A. Decosterd,2 Thomas Mercier,2 Chantal Csajka,1,2 Kevin Omondi,3 Bernhards Ogutu,3 **Gwénaëlle Carn,4 Jean-René Kiechel4**

**Affiliations:**
- 1. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland
- 2. Laboratory and Division of Clinical Pharmacology Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
- 3. Kenya Medical Research Institute, Kisumu, Kenya
- 4. **Drugs for Neglected Diseases initiative, Geneva, Switzerland**

**Session title:** 85. Poster Session B Presentations and Light Lunch

**Session time:** 12:00PM-1:45PM

**Location:** Exhibit Hall B/C

**Link:** [http://ow.ly/qiuZf](http://ow.ly/qiuZf)
DNDi webpage for ASTMH
http://ow.ly/qiJej

Follow us!
Facebook: facebook.com/dndi.org
Twitter: twitter.com/DNDi_HQ
YouTube: youtube.com/DNDiConnect

Website: www.dndi.org

DNDi 10th Anniversary site: connect2fightneglect.org

@DNDi_HQ
#NTDs
#Chagas
#TropMed2013

Media contact (on site):
Oliver Yun
Communications Manager, DNDi North America
Email: oyun@dndi.org
Mobile: +1-646-266-5216